Seeking Alpha

jimmy Turano » Comments » ARNA

  • Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly [View article]
    WHY DID YOU LEAVE 'MRNA' OUT OF YOUR ARTCLE? AFTER ALL, IT IS A NEW COMPANY, NEW CEO, MADE TWO PARTNERING DEALS WITHIN 60 DAYS THIS YEAR. SOLD OFF LONG ISLAND HEADQUARTERS TO 'PAR'. GOT UPFRONT MILESTONE PAYMENT THIS YEAR TOO.
    I MEAN SHOW A LITTLE RESPECT FOR A COMPANY THAT JUST WENT FROM $.27 CENTS TO $.75 CENTS WITHIN SEVERAL WEEKS. SO THEY MAY REVERSE SPLIT THE STOCK TO COMPLY WITH DE-LISTING. SO THEY MAY HAVE A NEWS RELEASE ABOUT 'GOING LETTER' OF CONCER. SO THEY HAVE HARDLY ANY EARNINGS & NO IMPROVED EARNINGS IN SIGHT. SO THEY HAVE A HUGE BURN RATE. SO THEY HAVE HIGH DEBT.
    SO THEIR SALES GROWTH IS TERRIBLE.
    THEY DO HAVE POTENTIAL!
    EVEN IF IT MAY TAKE 4-7 YEARS.
    IT IS A POSSIBILITY.
    THIS COMPANY SHOULD FIT YOU STORY SOMEWHERE ABOUT THE 'GOOD', 'THE BAD', 'THE UGLY' SOMEHOW.
    I MEAN THEY STILL EXIST AND SURVIVED SO FAR, WHY IS 'MRNA' NEVER COVERED BY SEEKING ALPHA?
    FORGET THEIR BALANCE SHEETS AND STATISTICS, LOOK AT WHO MANAGEMENT KNOWS AND WHAT THEY ARE ACCOMPLISHING.
    THEY HAVE MORE GOOD NEWS ANNOUNCEMENTS THAN THE WHITE HOUSE PRESS CORE. GIVE A LOOK!
    CHECK THEIR BACKGROUNDS OUT.
    CURRENT SHAREHOLDER WANT TO KNOW IF STOCK PRICE WILL CONTINUE INCREASE AND OR IS THIS A VIABLE LONG TERM PLAY AFTER ALL.

    Apr 02 10:14 am |Rating: +1 -4 |Link to Comment
  • Know Your Options When Investing in Biotech Stocks [View article]
    MDRNA INC(MRNA)
    What about a stock with no Phase lll in sight, high burn rate,hardly any earnings with no improved earnings in sight, high debt, and no significant accomplishments in 26 years, except lots of press releases?
    At least Roche recently made a deal with them, although it is a one time payment?
    COULDN'T THIS COMPANY, WHO HAS BEEN IN INTENSIVE CARE UNIT, COME OUT OF ITS COMA, OR SHOULD INVESTORS PULL THE PLUG?
    Mar 02 09:35 am |Rating: +1 0 |Link to Comment
  • Expecting a Strong Move in Arena Pharma [View article]
    Dan Pritch
    Good article, thank you.
    Maybe in the near future you may want to consider giving your prospective on 'NSTK'. I find and feel this is a story in a half.
    It has all the ingredients of something to really write about.
    Tremendous Hype, Chronic insider selling, Poor Sales, 10 year minus return on equity, Over played opportunities in the areas of Autism, Obesity, Diabetes, and RNAI. Lastly and truly, years away from potential FDA approvals with all their testing phases and hurdles they must jump perfectly to win approvals. One of the most overpriced Biotech's stocks in the market today in my opinion. Please consider Nstk as a future story of your personal perspective.
    Thank you,
    jt7423
    Aug 30 09:26 am |Rating: 0 0 |Link to Comment
More on ARNA by jimmy Turano
Comments by Ticker
A, AA, AAPL, ABK, ABPIQ.PK, ABT, ABX, ACAD, ACCP.OB, ACOR, ACTC.PK, ACTU, ADAT, ADLS, ADLS.OB, AEM, AET, AEZS, AGEN, AGN, AGU, AIB, AIR, AIS, AKS, AL, ALKS, ALL, ALNY, ALPMF.PK, ALTH, ALTR, ALXN, AMAG, AMGN, AMLN, AMP, AMZN, ANDS, ANPI, AOB, APA, APOL, APWR, ARAY, ARDM.OB, ARIA, ARNA, ARQL, ARRY,
jimmy Turano's
Comments Stats
298 comments
Rating: 91 (201 - 110 )